Skip to main content

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conferences:

Citi’s 2025 Global Healthcare Conference
Date/Time: Tuesday, December 2, 2025 at 2:30 p.m. ET

Evercore 8th Annual Healthcare Conference 
Date/Time: Wednesday, December 3, 2025 at 2:10 p.m. ET

The live conference webcasts will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcasts will be available for approximately 30 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on LinkedIn and X.

Investor Contact: 
Eva Stroynowski
ir@apellis.com
617.938.6229


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  231.35
-1.18 (-0.51%)
AAPL  272.60
-0.48 (-0.18%)
AMD  215.91
+0.56 (0.26%)
BAC  55.08
-0.20 (-0.37%)
GOOG  314.27
-0.28 (-0.09%)
META  663.57
-2.38 (-0.36%)
MSFT  485.79
-1.69 (-0.35%)
NVDA  189.11
+1.57 (0.84%)
ORCL  196.29
-0.92 (-0.47%)
TSLA  453.89
-0.54 (-0.12%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.